A new trial will test whether a set course of Brukinsa plus sonrotoclax, which target two pathways that drive hairy cell leukemia, can offer an alternative to chemotherapy.
|Videos|January 4, 2019
Physician Turns Personal Diagnosis to Educational Opportunity
Author(s)Brian Koffman, M.D.C.M
Brian Koffman is a family physician who used his own CLL diagnosis to start a group that informs other patients and their loved ones.
Advertisement
After being diagnosed with chronic lymphocytic leukemia (CLL) in 2005, physician Brian Koffman, M.D.C.M, created a blog to keep his friends and family updated on his disease.
Soon enough, the blog was reaching tens of thousands of readers each month. Koffman, who was also honored by CURE as a
Advertisement
Related to this article
Dr. Jacqueline Barrientos shares how a targeted therapy, a determined care team and a stranger’s generosity gave a 72-year-old man with hairy cell leukemia and kidney failure a second chance.
Dr. Robert Kreitman explains how CD22-targeted CAR T could help heavily pretreated patients.
Dr. Hope S. Rugo explains what KEYNOTE-B49 found about adding Keytruda to chemotherapy for PD-L1-positive, HR-positive, HER2-negative breast cancer.
Dr. Saum Ghodoussipour of Rutgers Cancer Institute answers top searched bladder cancer questions, from treatment and surgery side effects to sex and work.
An experimental treatment has kept one patient with heavily pretreated hairy cell leukemia free of detectable disease for more than two years, raising questions about whether CAR T-cell therapy could offer a path toward a cure.
Joy Maulik, MSN, FNP-C, explains why a prostate cancer diagnosis should be seen as a change in direction, not an ending, and how patients can lean on education, their providers and caregivers.
Dr. Morana Vojnic answers common questions about brain cancer, including diagnosis, tumor types, treatment effects, recurrence and life after treatment begins.
Advertisement
Advertisement
Trending on CURE
1
Precision Radiation Cuts 1-Year Pancreatic Cancer Recurrence to 20.2%
2
3 Prostate Cancer Results From ESMO 2026 Patients Should Know
3
Urologic Oncologist Answers Top Searched Questions in Bladder Cancer
4
Medicare to Cut Ostomy Suppliers to 6 Contracts: What Patients Need to Know
5